As California reduced the number of adults ages 19 to 64 years without health insurance by 15.5% from 2013 to 2014, Medi-Cal enrollment among the same age group rose from 12.9% to 19.2% during the same time period, according to new data from the UCLA Center for Health Policy Research.
As California reduced the number of adults ages 19 to 64 years without health insurance by 15.5% from 2013 to 2014, Medi-Cal enrollment among the same age group rose from 12.9% to 19.2% during the same time period, according to new data from the UCLA Center for Health Policy Research.
The researchers analyzed data from the California Health Interview Survey (CHIS) to determine the decline in the rate of uninsured. With the uninsured rate at 17.4%, this is the first time the percentage of people receiving Medi-Cal has exceeded the rate of people without insurance.
“The number of people without insurance, especially among low-income families and the middle class, is going in the right direction—down,” Ninez A. Ponce, PhD, MPP, associate center director at the UCLA Center for Health Policy Research, said in a statement. “But with 4.5 million still uninsured in the state, our job is not over yet.”
According to the data, while Medi-Cal coverage increased, employer-based coverage still continued to insure more than half (50.9%) of all nonelderly persons in the state of California. Enrollment in public programs other than Medi-Cal, such as Medicare and Aid to Infants and Mothers, declined to under 2% of the population.
Despite 13.6% of the nonelderly population remaining uninsured, UCLA determined that increases in coverage provide evidence that the Affordable Care Act (ACA) has significantly improved access to health insurance for millions of Californians.
“Comparing CHIS 2014 health insurance rates to those of the prior three years provides clear support for the importance of the impact ACA expansions have had on the health insurance status of nonelderly Californians.”
Earlier this week, Kaiser Health News reported the quest to fold California Children’s Services into Medi-Cal, which would place the program, serving 180,000 children, into managed care in phases through 2019.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More